We have run across a number of medical device startups that seem to think of communications as a post-clearance function or even a luxury. They pour everything into engineering, clinical validation, and the regulatory gauntlet. The story can wait, they reason, until the data is locked and the FDA letter arrives.
That logic is understandable. It is also expensive.
By the time they finally hire a communications or public relations consultant or begin building a deliberate product or company narrative, the market has already formed opinions. More often than not, no opinions at all. The technology may be strong; their story is not. And in medtech, the absence of a clear, credible narrative is rarely neutral. It is a disadvantage.
Founders and early teams are usually technical or clinical by training. Their instinct is to protect the science, conserve cash, and avoid any appearance of overclaiming before clearance. Communications can feel soft, discretionary, or even risky under the constraints of promotional rules.
Budgets reinforce the bias. Every dollar that does not go toward trials, engineering, or regulatory consultants is scrutinized. PR and strategic messaging often sit near the bottom of the priority list until a fundraising round or commercial launch forces the issue.
There is also a quiet belief that strong technology will eventually speak for itself. It rarely does. Investors, hospital decision-makers, potential partners, and key opinion leaders evaluate more than performance data. They evaluate confidence, clarity, and context. A company that has spent years developing a device but has never consistently articulated why the problem matters, how the solution is differentiated, or what it means for the future of care starts from behind.
The cost shows up in several places.
First, visibility windows close. Regulatory milestones, clinical readouts, and financing rounds are natural moments for meaningful coverage and relationship-building. Companies that have not already established a point of view and the relationships to amplify it often miss these windows or scramble reactively.
Second, category positioning is left to others. In crowded therapeutic areas, the companies that define the problem and the standard of progress tend to own the conversation. Arriving late means competing inside someone else’s framing.
Third, talent and partnership conversations become harder. Strong engineers, clinicians, and commercial leaders prefer to join organizations that already demonstrate market presence and strategic coherence. The same is true for strategic partners and sophisticated investors. A polished data room is necessary. A coherent external narrative is increasingly expected.
Finally, the work of building authority simply takes time. Media relationships, thought leadership platforms, consistent messaging, and internal alignment cannot be manufactured in a six-week launch sprint. They compound. Starting late means starting with less equity.
Investing in communications early does not mean aggressive product promotion before clearance. It means treating narrative and market understanding as strategic infrastructure that runs parallel to product development.
It means clarifying the problem the company exists to solve and the category it intends to lead—long before the device is commercially available. It means giving executives a disciplined way to talk about the work without running afoul of regulatory boundaries. It means building selective visibility around the science, the unmet need, and the leadership team’s point of view so that when milestones arrive, the market already has a framework for interpreting them.
Medical device innovation is hard enough. The market does not award extra points for arriving with a strong product and an underdeveloped story. Authority is built from the inside out, over time, through consistent alignment between what a company is creating and how it is understood. Most startups discover this later than they should. The ones that treat communications as a strategic function from the earlier stages tend to find the market already listening when they are ready to speak.